These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1440 related items for PubMed ID: 12036928

  • 1. The efficacy of ErbB receptor-targeted anticancer therapeutics is influenced by the availability of epidermal growth factor-related peptides.
    Motoyama AB, Hynes NE, Lane HA.
    Cancer Res; 2002 Jun 01; 62(11):3151-8. PubMed ID: 12036928
    [Abstract] [Full Text] [Related]

  • 2. Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors.
    Alimandi M, Wang LM, Bottaro D, Lee CC, Kuo A, Frankel M, Fedi P, Tang C, Lippman M, Pierce JH.
    EMBO J; 1997 Sep 15; 16(18):5608-17. PubMed ID: 9312020
    [Abstract] [Full Text] [Related]

  • 3. Phosphatidylinositol 3-kinase recruitment by p185erbB-2 and erbB-3 is potently induced by neu differentiation factor/heregulin during mitogenesis and is constitutively elevated in growth factor-independent breast carcinoma cells with c-erbB-2 gene amplification.
    Ram TG, Ethier SP.
    Cell Growth Differ; 1996 May 15; 7(5):551-61. PubMed ID: 8732665
    [Abstract] [Full Text] [Related]

  • 4. Growth regulation of human breast and ovarian tumor cells by heregulin: Evidence for the requirement of ErbB2 as a critical component in mediating heregulin responsiveness.
    Lewis GD, Lofgren JA, McMurtrey AE, Nuijens A, Fendly BM, Bauer KD, Sliwkowski MX.
    Cancer Res; 1996 Mar 15; 56(6):1457-65. PubMed ID: 8640840
    [Abstract] [Full Text] [Related]

  • 5. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P, Allegrini PR, Brandt R, Brueggen J, Cozens R, Fabbro D, Grosios K, Lane HA, McSheehy P, Mestan J, Meyer T, Tang C, Wartmann M, Wood J, Caravatti G.
    Cancer Res; 2004 Jul 15; 64(14):4931-41. PubMed ID: 15256466
    [Abstract] [Full Text] [Related]

  • 6. Epidermal growth factor receptor, c-erbB2 and c-erbB3 receptor interaction, and related cell cycle kinetics of SK-BR-3 and BT474 breast carcinoma cells.
    Brockhoff G, Heiss P, Schlegel J, Hofstaedter F, Knuechel R.
    Cytometry; 2001 Aug 01; 44(4):338-48. PubMed ID: 11500850
    [Abstract] [Full Text] [Related]

  • 7. Heregulin-beta is especially potent in activating phosphatidylinositol 3-kinase in nontransformed human mammary epithelial cells.
    Ram TG, Hosick HL, Ethier SP.
    J Cell Physiol; 2000 Jun 01; 183(3):301-13. PubMed ID: 10797304
    [Abstract] [Full Text] [Related]

  • 8. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

  • 9. Growth stimulation of non-small cell lung cancer cell lines by antibody against epidermal growth factor receptor promoting formation of ErbB2/ErbB3 heterodimers.
    Maegawa M, Takeuchi K, Funakoshi E, Kawasaki K, Nishio K, Shimizu N, Ito F.
    Mol Cancer Res; 2007 Apr 01; 5(4):393-401. PubMed ID: 17426253
    [Abstract] [Full Text] [Related]

  • 10. Peptide aptamers with binding specificity for the intracellular domain of the ErbB2 receptor interfere with AKT signaling and sensitize breast cancer cells to Taxol.
    Kunz C, Borghouts C, Buerger C, Groner B.
    Mol Cancer Res; 2006 Dec 01; 4(12):983-98. PubMed ID: 17189388
    [Abstract] [Full Text] [Related]

  • 11. The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
    Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y.
    Oncogene; 1998 Mar 12; 16(10):1249-58. PubMed ID: 9546426
    [Abstract] [Full Text] [Related]

  • 12. Growth inhibitory effects of the dual ErbB1/ErbB2 tyrosine kinase inhibitor PKI-166 on human prostate cancer xenografts.
    Mellinghoff IK, Tran C, Sawyers CL.
    Cancer Res; 2002 Sep 15; 62(18):5254-9. PubMed ID: 12234993
    [Abstract] [Full Text] [Related]

  • 13. Heregulin beta1-activated phosphatidylinositol 3-kinase enhances aggregation of MCF-7 breast cancer cells independent of extracellular signal-regulated kinase.
    Tan M, Grijalva R, Yu D.
    Cancer Res; 1999 Apr 01; 59(7):1620-5. PubMed ID: 10197638
    [Abstract] [Full Text] [Related]

  • 14. ErbB kinases and NDF signaling in human prostate cancer cells.
    Grasso AW, Wen D, Miller CM, Rhim JS, Pretlow TG, Kung HJ.
    Oncogene; 1997 Nov 27; 15(22):2705-16. PubMed ID: 9400997
    [Abstract] [Full Text] [Related]

  • 15. Constitutive activation of the neuregulin-1/ErbB receptor signaling pathway is essential for the proliferation of a neoplastic Schwann cell line.
    Frohnert PW, Stonecypher MS, Carroll SL.
    Glia; 2003 Aug 27; 43(2):104-18. PubMed ID: 12838503
    [Abstract] [Full Text] [Related]

  • 16. Augmentation of a humanized anti-HER2 mAb 4D5 induced growth inhibition by a human-mouse chimeric anti-EGF receptor mAb C225.
    Ye D, Mendelsohn J, Fan Z.
    Oncogene; 1999 Jan 21; 18(3):731-8. PubMed ID: 9989823
    [Abstract] [Full Text] [Related]

  • 17. Distinct roles for phosphoinositide 3-kinase, mitogen-activated protein kinase and p38 MAPK in mediating cell cycle progression of breast cancer cells.
    Neve RM, Holbro T, Hynes NE.
    Oncogene; 2002 Jul 04; 21(29):4567-76. PubMed ID: 12085235
    [Abstract] [Full Text] [Related]

  • 18. Epidermal growth factor receptor (HER1) tyrosine kinase inhibitor ZD1839 (Iressa) inhibits HER2/neu (erbB2)-overexpressing breast cancer cells in vitro and in vivo.
    Moulder SL, Yakes FM, Muthuswamy SK, Bianco R, Simpson JF, Arteaga CL.
    Cancer Res; 2001 Dec 15; 61(24):8887-95. PubMed ID: 11751413
    [Abstract] [Full Text] [Related]

  • 19. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H, Akita RW, Sliwkowski MX, Maihle NJ.
    Cancer Res; 2001 Jun 01; 61(11):4467-73. PubMed ID: 11389077
    [Abstract] [Full Text] [Related]

  • 20. The phosphatidylinositol 3'-kinase pathway is a dominant growth factor-activated cell survival pathway in LNCaP human prostate carcinoma cells.
    Lin J, Adam RM, Santiestevan E, Freeman MR.
    Cancer Res; 1999 Jun 15; 59(12):2891-7. PubMed ID: 10383151
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 72.